News Search Results
Apr 13, 2026, 09:00 ET Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors
Chief Executive Officer of CorMedix Inc. Prior to joining CorMedix, he spent eleven years at Amneal Pharmaceuticals, where he held several senior leadership roles, including Chief Commercial Officer of Amneal Specialty and Senior Vice President of Corporate Development and International Operations. He
More news about: Airway Therapeutics
Apr 13, 2026, 09:00 ET Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors
Chief Executive Officer of CorMedix Inc. Prior to joining CorMedix, he spent eleven years at Amneal Pharmaceuticals, where he held several senior leadership roles, including Chief Commercial Officer of Amneal Specialty and Senior Vice President of Corporate Development and International Operations. He
More news about: Airway Therapeutics
Apr 13, 2026, 09:00 ET Airway Therapeutics beruft den führenden Biopharma-Experten Joe Todisco in den Vorstand
Officer von CorMedix Inc. Vor seinem Eintritt bei CorMedix war er elf Jahre lang bei Amneal Pharmaceuticals tätig, wo er verschiedene Führungspositionen innehatte, darunter die des Chief Commercial Officer von Amneal Specialty und des Senior Vice President of Corporate Development and International Operations.
More news about: Airway Therapeutics
Apr 13, 2026, 09:00 ET Airway Therapeutics nombra a Joe Todisco miembro de su Consejo de Administración
presidente y consejero delegado de CorMedix Inc. Antes de unirse a CorMedix, trabajó once años en Amneal Pharmaceuticals, donde ocupó varios cargos de alta dirección, incluyendo el de director comercial de Amneal Specialty y vicepresidente sénior de Desarrollo Corporativo y Operaciones Internacionales. También
More news about: Airway Therapeutics
Apr 13, 2026, 09:00 ET Airway Therapeutics nomme Joe Todisco, leader du secteur biopharmaceutique, à son conseil d'administration
actuellement président du conseil et président-directeur général de CorMedix Inc. Avant de rejoindre CorMedix, il a travaillé pendant onze ans chez Amneal Pharmaceuticals, où il a occupé plusieurs postes de haut niveau, notamment celui de directeur commercial d'Amneal Specialty et de vice-président principal
More news about: Airway Therapeutics
Apr 01, 2026, 05:27 ET American Parkinson Disease Association Kicks Off Awareness Month with Launch of New Public Service Announcement
research that will lead to better treatments and, ultimately, a cure. Every effort makes a difference.APDA is grateful to Champion Partners Amneal Pharmaceuticals and Sunrise Senior Living for supporting their efforts to help everyone impacted by PD, not just this April, but throughout the entire
More news about: American Parkinson Disease Association, Inc.
Mar 17, 2026, 09:00 ET 美國涅狄格州檢察總長辦公室: 如果您曾在美國購買特定處方學名藥您可能得以自目前及未來的和解中獲得款項
針對消費者指控學名藥廠商使學名處方藥價格被人為抬高而支付不合理高價的訴訟，目前已與部分藥廠達成進一步和解協議。和解被告為 Bausch Health US, LLC、Bausch Health Americas, Inc. 及 Lannett Company, Inc. 訴訟會針對其他所有非和解被告藥廠繼續進行：Actavis、Amneal、Ascend、Aurobindo、Breckinridge、Citron、Dr. Reddy's、Emcure、Fougera（參見 Sandoz）、G&W、Glenmark、Greenstone、Lupin、Mallinckrodt（破產）、Mayne Pharma、Mylan、Par Pharmaceutical（破產）、Perrigo、Pfizer、Sandoz、Sun、Taro、Teligent（破產）、Teva、Upsher-Smith、Wockhardt
More news about: Connecticut Office of the Attorney General
Mar 17, 2026, 09:00 ET 康涅狄格州总检察长办公室: 如果您在美国购买了某些仿制处方药您可能有机会从当前和未来的和解中获得赔偿
在涉及消费者为仿制处方药支付了人为抬高的价格的诉讼中，又与部分仿制处方药制造商达成和解。和解被告为 Bausch Health US, LLC、Bausch Health Americas, Inc. 和 Lannett Company, Inc.。 针对下述所有未和解被告药品制造商的诉讼仍继续进行：Actavis、Amneal、Ascend、Aurobindo、Breckinridge、Citron、Dr. Reddy's、Emcure、Fougera（即 Sandoz）、G&W、Glenmark、Greenstone、Lupin、Mallinckrodt（破产）、Mayne Pharma、Mylan、Par Pharmaceutical（破产）、Perrigo、Pfizer、Sandoz、Sun、Taro、Teligent（破产）、Teva、Upsher-Smith、Wockhardt
More news about: Connecticut Office of the Attorney General
Mar 17, 2026, 09:00 ET Connecticut Office of the Attorney General: If You Bought Certain Generic Prescription Drugs in the United States, You Could Get Money from Current and Future Settlements
Americas, Inc., and Lannett Company, Inc. Lawsuits continue against all other Non-Settling Defendant drug manufacturers: Activis, Amneal, Ascend, Aurobindo, Breckinridge, Citron, Dr. Reddy's, Emcure, Fougera (See Sandoz), G&W, Glenmark, Greenstone, Lupin, Mallinckrodt (bankruptcy),
More news about: Connecticut Office of the Attorney General
Mar 17, 2026, 09:00 ET Oficina del Fiscal General de Connecticut: Si compró ciertos medicamentos genéricos recetados en los Estados Unidos podría obtener dinero de conciliaciones actuales y conciliaciones futuras
Inc. y Lannett Company, Inc. Las demandas continúan contra todos los demás fabricantes de medicamentos Demandados no conciliadores: Actavis, Amneal, Ascend, Aurobindo, Breckinridge, Citron, Dr. Reddy's, Emcure, Fougera (véase Sandoz), G&W, Glenmark, Greenstone, Lupin, Mallinckrodt (quiebra),
More news about: Connecticut Office of the Attorney General
Mar 17, 2026, 03:46 ET GLP-1 Receptor Agonist Market to Hit USD 78.4 Billion by 2032, Growing at a CAGR of 3.66% with Rising Demand for Metabolic Disease Therapies | MarkNtel Advisors
Inc.SanofiGlaxoSmithKline plcBoehringer Ingelheim International GmbHAmgen Inc.Hanmi Pharmaceutical Co., Ltd.Amneal Pharmaceuticals, Inc.Biocon Ltd.Glenmark Pharmaceuticals Ltd.Takeda Pharmaceutical Co. Ltd.Sun Pharmaceutical Industries
More news about: MarkNtel Advisors
Feb 13, 2026, 11:26 ET Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
million prescriptions annually across a portfolio of over 290 medicines."As Amneal has grown and diversified, our brand needed to evolve with us," said Chirag Patel, Co-Founder and Co-CEO of Amneal Pharmaceuticals. "This new brand reflects who we are today and where we are headed.
More news about: Equity Insider
Jan 27, 2026, 18:02 ET TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January
More news about: S&P Dow Jones Indices
Dec 22, 2025, 16:00 ET mAbxience und Amneal geben FDA-Zulassung für Denosumab-Biosimilars unter Bezugnahme auf Prolia® und XGEVA® bekannt
mAbxience, eine mehrheitlich im Besitz von Fresenius Kabi und teilweise im Besitz von Insud Pharma befindliche Unternehmensgruppe, und Amneal Pharmaceuticals, Inc. („Amneal" oder das „Unternehmen") (NASDAQ: AMRX) gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration)
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience e Amneal annunciano l'approvazione da parte della FDA dei biosimilari di denosumab con riferimento a Prolia® e XGEVA®
dicembre 2025 /PRNewswire/ -- mAbxience, un gruppo controllato da Fresenius Kabi con partecipazione parziale di Insud Pharma, e Amneal Pharmaceuticals, Inc. ("Amneal" o la "Società") (NASDAQ: AMRX), hanno annunciato oggi che la Food and Drug Administration (FDA) statunitense ha approvato le loro domande
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience y Amneal anuncian la aprobación de la FDA de biosimilares de denosumab referidos a Prolia® y XGEVA®
de 2025 /PRNewswire/ -- mAbxience, grupo participado mayoritariamente por Fresenius Kabi y parcialmente por Insud Pharma, y Amneal Pharmaceuticals, Inc. («Amneal» o la «Compañía») (NASDAQ: AMRX), han anunciado hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience et Amneal annoncent l'autorisation par la FDA des biosimilaires du denosumab référencés Prolia® et XGEVA®
décembre 2025 /PRNewswire/ -- mAbxience, un groupe détenu majoritairement par Fresenius Kabi et partiellement par Insud Pharma, et Amneal Pharmaceuticals, Inc. (« Amneal » ou « la Société ») (NASDAQ : AMRX), ont annoncé aujourd'hui que la Food and Drug Administration (FDA) américaine avait approuvé leurs
More news about: mAbxience
Nov 04, 2025, 03:01 ET BioSpace Announces 2026 Best Places to Work in Life Sciences Winners
Amneal Pharmaceuticals and
More news about: BioSpace
Sep 25, 2025, 15:25 ET Apiject Submits Innovative Prefilled Single Dose Injection Device for FDA Approval
Connector are easily push-assembled by a healthcare professional just prior to patient injection. Apiject recently announced a strategic collaboration with Amneal Pharmaceuticals, an integrated U.S.-based biopharmaceutical company, to expand domestic production of Apiject's BFS-based injectable platform at Amneal's
More news about: ApiJect Systems, Corp.
Sep 24, 2025, 17:31 ET Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight
cases: ATZUMI (dihydroergotamine mesylate), SYMBRAVO (meloxicam and rizatriptan), and BREKIYA (dihydroergotamine mesylate) by Amneal Pharmaceuticals. QUTENZA (capsaicin) 8% topical system is expected to report topline data in Q4 2025, with Averitas Pharma planning to file
More news about: DelveInsight Business Research, LLP
Sep 22, 2025, 11:13 ET Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033, Report by DataM Intelligence
advancement in treatment, offering continuous symptom control and greater convenience for patients. Similarly, companies like Supernus Pharmaceuticals and Amneal Pharmaceuticals have also made notable contributions with approvals for ONAPGO and CREXONT. In addition to pharmaceutical innovation, increased
More news about: DataM Intelligence 4 Market Research LLP
Aug 05, 2025, 07:35 ET A Knight Therapeutics anuncia a submissão regulatória de CREXONT® (Carbidopa e Levodopa) Cápsulas de Liberação Prolongada no México
desenvolvida para o tratamento da doença de Parkinson. Em janeiro de 2024, a Knight anunciou a celebração de um acordo com a Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal") para obtenção dos direitos exclusivos da aprovação regulatória e comercialização do Crexont® no Canadá e na América
More news about: Knight Therapeutics Inc.
Aug 05, 2025, 07:35 ET Knight Therapeutics anuncia la presentación regulatoria de las cápsulas de liberación prolongada CREXONT® (Carbidopa y Levodopa) en México
para el tratamiento de la enfermedad de Parkinson. En enero de 2024, Knight anunció que había firmado un acuerdo con Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal") para obtener los derechos exclusivos para solicitar la aprobación regulatoria y comercializar CREXONT ® en Canadá
More news about: Knight Therapeutics Inc.
Jun 26, 2025, 17:46 ET Post-Traumatic Stress Disorder Market Set to Expand Significantly During the Study Period (2020-2034) with Pipeline Innovation and Unmet Needs | DelveInsight
LEMS companies including Jacobus Pharmaceutical Company, Inc., Zydus Cadila, BioMarin, Catalyst Pharma, Novartis AG, Shenox Pharmaceuticals, LLC, Amneal Pharmaceuticals LLC, Alvogen, Apnar Pharma, Novitium Pharma, among others.
More news about: DelveInsight Business Research, LLP
May 28, 2025, 17:31 ET Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight
patients. Later, in July 2020, the US FDA approved the first generic version of DEMSER oral capsules, manufactured by Amneal Pharmaceuticals, marking the initial generic approval for DEMSER in the US. In May 2025, Merck announced
More news about: DelveInsight Business Research, LLP